Uric acid in Parkinson's disease
Identifieur interne : 003125 ( Main/Merge ); précédent : 003124; suivant : 003126Uric acid in Parkinson's disease
Auteurs : Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-09-15.
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Uric Acid.
- chemical , therapeutic use : Antioxidants, Uric Acid.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22139
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002051
- to stream Istex, to step Curation: 002051
- to stream Istex, to step Checkpoint: 001103
- to stream PubMed, to step Corpus: 002155
- to stream PubMed, to step Curation: 002155
- to stream PubMed, to step Checkpoint: 002004
- to stream Ncbi, to step Merge: 002208
- to stream Ncbi, to step Curation: 002208
- to stream Ncbi, to step Checkpoint: 002208
Links to Exploration step
ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22139</idno>
<idno type="url">https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002051</idno>
<idno type="wicri:Area/Istex/Curation">002051</idno>
<idno type="wicri:Area/Istex/Checkpoint">001103</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Schlesinger I:uric:acid:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18618666</idno>
<idno type="wicri:Area/PubMed/Corpus">002155</idno>
<idno type="wicri:Area/PubMed/Curation">002155</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002004</idno>
<idno type="wicri:Area/Ncbi/Merge">002208</idno>
<idno type="wicri:Area/Ncbi/Curation">002208</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002208</idno>
<idno type="wicri:Area/Main/Merge">003125</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-09-15">2008-09-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1653">1653</biblScope>
<biblScope unit="page" to="1657">1657</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<idno type="DOI">10.1002/mds.22139</idno>
<idno type="ArticleID">MDS22139</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidants (therapeutic use)</term>
<term>Humans</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Uric Acid (blood)</term>
<term>Uric Acid (therapeutic use)</term>
<term>neuroprotection</term>
<term>urate</term>
<term>uric acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.22139"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22139</idno>
<idno type="url">https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002051</idno>
<idno type="wicri:Area/Istex/Curation">002051</idno>
<idno type="wicri:Area/Istex/Checkpoint">001103</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Schlesinger I:uric:acid:in</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-09-15">2008-09-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1653">1653</biblScope>
<biblScope unit="page" to="1657">1657</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<idno type="DOI">10.1002/mds.22139</idno>
<idno type="ArticleID">MDS22139</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>neuroprotection</term>
<term>urate</term>
<term>uric acid</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease.</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="doi">10.1002/mds.22139</idno>
<idno type="RBID">pubmed:18618666</idno>
<idno type="pmid">18618666</idno>
<idno type="wicri:Area/PubMed/Corpus">002155</idno>
<idno type="wicri:Area/PubMed/Curation">002155</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002004</idno>
<idno type="wicri:Area/Ncbi/Merge">002208</idno>
<idno type="wicri:Area/Ncbi/Curation">002208</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002208</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Uric acid in Parkinson's disease.</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidants (therapeutic use)</term>
<term>Humans</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Uric Acid (blood)</term>
<term>Uric Acid (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB |texte= Uric acid in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |